MARX Biotech Co., Ltd.

As of June 30, 2026, MARX Biotech Co., Ltd. carries a market capitalization of 2.83B, placing it among publicly traded companies globally. Its enterprise value stands at 2.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, MARX Biotech Co., Ltd. has 521.98M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, MARX Biotech Co., Ltd. maintains a current ratio of 1.67, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, MARX Biotech Co., Ltd.'s stock has declined approximately 0.49% over the past 52 weeks. The 50-day moving average sits at 4.33, while the 200-day moving average is 5.22.

As of June 30, 2026, MARX Biotech Co., Ltd. holds 73.31M in cash and equivalents against 219.99M in total debt, resulting in a net debt position of 145.69M. Total book value stands at 288.60M, with working capital of 156.36M providing operational flexibility.

MARX Biotech Co., Ltd.'s most recent stock split took place on July 11, 2025.